)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
ImpediMed
ImpediMed (IPD) investor relations material
ImpediMed Q1 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2027 earnings summary29 Oct, 2026
Executive summary
Q1 FY27 revenue was $3.8m, up 6% QoQ; ARR was $14.9m, up 3% QoQ, and $16.1m in constant currency, up 12% YoY.
Operating cash outflow was $2.462m, down $2.4m QoQ; quarter-end cash was $11.579m, equal to 4.7 quarters of operating cash flow.
BCRL sales missed expectations; sales leadership changed and the team is being rebuilt as expanded clinical applications and care standards support longer-term growth.
Financial highlights
Revenue was $3.8m, up 6% QoQ; customer receipts were $4.2m vs $4.3m in Q4 FY26.
Core Business TCV was $4.4m vs $5.4m in Q4 FY26, mainly due to fewer contracts up for renewal; renewed contract prices rose 18% on average.
ARR was $14.9m, up $0.5m or 3% QoQ; constant-currency ARR was $16.1m, up $1.7m or 12% YoY.
47 SOZO units sold globally: 28 in the U.S. and 19 in ROW; patient tests totaled 94,000, up 8% QoQ and 22% YoY.
Outlook and guidance
Q2 priorities include filling U.S. sales roles, progressing the pipeline, targeting NAPBC opportunities, and expanding customer programs.
Growth actions include advancing oncology partnerships, using a KOL partnership in Longevity & Wellness, and generating leads at sector conferences.
Heart Health priorities include supporting studies and securing a medical-device collaboration; investment will remain paced to commercial traction.
Sales-team hiring and productivity ramp may affect cash-flow breakeven timing; initiatives to mitigate the impact are being evaluated.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from ImpediMed
- Revenue up 15% to $14.6M; net loss $24.9M; $15.3M capital raised for growth and debt reduction.IPD
H2 2026 - Q4 FY26 delivered revenue growth, record cash receipts, and expanded reimbursement coverage.IPDQ4 2026
- Shareholders approved a major capital raise to fund growth and reduce debt, with results pending.IPDEGM 2026
- $15.2M equity raise funds SOZO®-driven US expansion, targeting FY28 cashflow breakeven.IPDInvestor presentation
- A$15.2 million capital raise and cost cuts set a path to breakeven by FY28.IPDTrading update
- Q3 FY26 revenue reached $3.5M, with expanded US reimbursement and new CEO appointed.IPDQ3 2026
- New CEO appointed to drive U.S. growth as Q3 shows solid sales and ongoing cost discipline.IPDInvestor update
- Revenue up 25% to $7.5M, with strong recurring growth and expanded US reimbursement.IPDH1 2026
- SOZO Core Business and ARR grew 14% and 18% despite a 9% revenue drop, with break-even targeted by July 2025.IPDH2 2024
Next ImpediMed earnings date
AGM 202618 Nov, 2026
ImpediMed
Next ImpediMed earnings date
AGM 202618 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
ImpediMed Limited is an Australian medical technology company specializing in bioimpedance spectroscopy (BIS) technology for non-invasive health assessments. The company’s primary products focus on the early detection, monitoring, and management of lymphedema, as well as body composition and fluid status assessments. ImpediMed’s technology is used in healthcare settings to support patient care in oncology, renal health, and other medical fields where fluid management is critical. ImpediMed Limited is headquartered in Brisbane, Australia, and its shares are listed on the ASX.